Here are four things to know:
1. The study will test the ALLOB, the company’s allogeneic bone-cell therapy product.
2. Bone Therapeutics anticipates having efficacy and safety data for the 32 patients by mid-2019.
3. The study will follow the patients for 12 months.
4. The interim results of the study revealed bone formation and pain improvement in patients with ALLOB.
More articles on biologics:
Positive clinical trial results for human dermal fibroblast injection CybroCell: 7 key insights
Stempeutics Research inks deal with Alkem Laboratories for osteoarthritis drug: 3 insights
Bioventus to be sole US distributor of Supartz Fx through May 2028 — 3 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
